Show document

A+ | A- | | SLO | ENG

Title: Zdravljenje razsejanega karcinoma rektuma z imunoterapijo : klinični primer Authors: ID Drobnič, Alja (Author) ID Boc, Marko (Author) ID Volk, Neva (Author) Files: PDF - Presentation file, download (91,18 KB) MD5: 28B9724A596E4FC11EAF1412E5A81F03   Language: Slovenian Typology: 1.08 - Published Scientific Conference Contribution Organization: OI - Institute of Oncology Abstract: Rak debelega črevesa in danke je med najpogostejšimi raki. Ob postavitvi diagnoze ima 23 % bolnikov razsejano obliko bolezni, 5-letno čisto preživetje bolnikov z razsejano boleznijo je 9 %. Z imunoterapijo lahko pri tumorjih z mutacijami v MMR (mismatch repair) genih oziroma visoko mikrosatelitno nestabilnostjo (MSI-H) dosežemo dolgotrajen odgovor na zdravljenje. V nadaljevanju je predstavljen primer bolnika na zdravljenju s pembrolizumabom, pri katerem smo dosegli regres bolezni. Keywords: rak rektuma, sistemsko zdravljenje, rak prebavil Publication status: Published Publication version: Version of Record Place of publishing: Ljubljana Publisher: Onkolološki inštitut Year of publishing: 2022 Number of pages: Str. 46-48 PID: 20.500.12556/DiRROS-16051  UDC: 616.3 COBISS.SI-ID: 135648003  Copyright: by Authors Note: Nasl. z nasl. zaslona; Opis vira z dne 29. 12. 2022; Publication date in DiRROS: 12.01.2023 Views: 856 Downloads: 263 Metadata:    Cite this work Plain text BibTeX EndNote XML EndNote/Refer RIS ABNT ACM Ref AMA APA Chicago 17th Author-Date Harvard IEEE ISO 690 MLA Vancouver : Copy citation

Share: Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a monograph

Title:	Tumorji prebavil : Standardi in perspektive
Editors:	Marko Boc, Tanja Mesti
Place of publishing:	Ljubljana
Publisher:	Onkološki inštitut, Sekcija za internistično onkologijo, Katedra za onkologijo
Year of publishing:	2022
ISBN:	978-961-7029-55-0
COBISS.SI-ID:	133694211

Secondary language

Language:	English
Title:	Treatment of disseminated rectal carcinoma with immunotherapy : a case report
Abstract:	Colorectal cancer is among the most common cancers. At diagnosis, 23% of patients have disseminated form of the disease, the 5-year net survival of patients with disseminated disease is 9%. With immunotherapy in tumors with mutations in MMR (mismatch repair) genes or high microsatellites instability (MSI-H), we can achieve a long-term response to treatment. We present a case report of a patient treated with pembrolizumab, in whom we achieved disease regression.

Back